IND submission is a major milestone in the life of your drug. We can provide all supporting analytical data to help ensure a smooth application process.
We have the expertise, flexibility, and resources to provide a full range of pharmaceutical API custom development services at every stage of the lifecycle.
We can provide lab-, kilo- and pilot-scale manufacturing for preclinical studies and all phases of clinical trials, supplying milligram to kilogram quantities.
Cambrex brings more than 40 years of generic API manufacturing experience to its pharmaceutical partners. From our sites in Italy, Sweden, and the USA, we are a leading global supplier of generic APIs.
Drug substance tech transfer sounds so simple on the surface, but it’s a complex activity carrying a number of technical, regulatory, and quality risks.
At Snapdragon Chemistry, now part of Cambrex, our chemists specialize in creating custom solutions and technologies to take on your toughest process development and production challenges. This includes expertise in designing and building reactors that enable seamless technology transfer as a process scales up for commercial manufacturing.
At Cambrex, we provide a range of technologies equipped to solve your API manufacturing challenges, and we are flexible enough to handle the most complex molecules.
You can rely on our extensive portfolio of analytical development solutions and testing services to rapidly advance your molecule for the greatest chance of success.
Cambrex offers a comprehensive suite of testing services for complex biopharmaceuticals including standalone analytical R&D, method validation, release testing, ICH stability, and routine QC testing.
We’re solid state chemistry experts who can deliver timely, phase-appropriate solutions to optimize the physical stability of your API, develop a more bioavailable formulation or overcome other challenges.
Cambrex’s experienced analysts are well-equipped to ensure microbial testing is of the highest quality for our customers and delivered with a quick and reliable turnaround.
Cambrex and Q1 Scientific’s stability storage and sample management capabilities provide a variety of pharmaceutical storage conditions, with walk-in and reach-in chambers that meet all ICH Q1A requirements.
Cambrex offers extensive development services tailored to meet your drug product needs in early development. From pre-formulation to Phase II, we ensure your products are developed with speed, flexibility, and quality in mind.
Whether you need rapid development, flexible manufacturing solutions, or high-quality production, Cambrex is your trusted partner for advancing your drug product from concept to the clinic.
Cambrex is here to support you in early-phase development. Our development experts apply their ingenuity and skill to address your unique challenges.
Our teams of creative problem-solvers work closely with you to accelerate drug development timelines, optimize processes, and meet regulatory requirements.
We understand that the commercial phase of drug development can be challenging, especially when it comes to manufacturing at scale and meeting changing market demands.
Cambrex is a leading global supplier of more than 70 generic APIs, as well as intermediates and derivatives.
Pharmaceutical companies of all sizes are often challenged to identify a CDMO partner that can truly grow with their candidates in early development. An organization may kick off drug development with one proposed indication and smaller production volumes in mind but, as clinical results emerge and indications are added, additional API demands may begin to outstrip their partner’s capacity.
For drug developers commercializing orphan drugs, the search to find small-scale commercial partners presents another unique challenge. Over the past two years, the FDA has approved more orphan drugs than non-orphan drugs, often with fast-track status. To meet this need, CDMOs must be able to scale quickly within their facilities to help their clients progress therapies from early clinical toward validation and commercial launch.
Cambrex recently invested $30 million in the expansion of its API development and small-scale commercial capabilities in High Point, North Carolina. On this webinar, Brian Swierenga, VP of Operations and Site Director, High Point and Dan Bowles, Senior Director of Chemical Development, High Point, discuss how their facility and the Cambrex network are evolving to enhance capabilities and accelerate API development.
Thank you for your interest in our content.
Peptide-based therapeutics are rapidly gaining clinical and commercial success, leading to the need for technologies to develop and scale these candidates. In this webinar, our team of experts discuss technologies and case studies surrounding liquid-phase peptide synthesis (LPPS), peptide crystallization, method development for peptide impurity analysis and more.
Cambrex offers innovative capabilities and technology to develop and manufacture synthetic molecules – peptides, oligonucleotides, synthetic DNA, block copolymers, polymeric linkers, functionalized dendrimers and modified carbohydrate polymers – for use in drug substances, medical devices and diagnostic agents.
In our recent article in European Pharmaceutical Review, Matthew Bio, Chief Scientific Officer at Cambrex, discusses how continuous manufacturing has become integral to the pharmaceutical industry, its uses in addressing technical challenges and complex chemistries and its expected growth in the coming years.